Shares of West Pharmaceutical Services Inc. (NYSE:WST) reached a new 52-week high on Tuesday . The stock traded as high as $82.28 and last traded at $81.65, with a volume of 59,176 shares trading hands. The stock had previously closed at $81.56.

Several analysts have weighed in on WST shares. Janney Montgomery Scott reiterated a “buy” rating and set a $90.00 target price (up previously from $69.00) on shares of West Pharmaceutical Services in a research note on Friday, May 13th. Jefferies Group boosted their target price on shares of West Pharmaceutical Services from $67.00 to $77.00 and gave the company a “hold” rating in a research note on Friday, July 29th. Finally, Zacks Investment Research upgraded shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and set a $91.00 target price for the company in a research note on Friday, August 5th.

The company has a 50-day moving average of $79.33 and a 200-day moving average of $71.57. The stock has a market capitalization of $5.96 billion and a price-to-earnings ratio of 59.26.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings results on Thursday, July 28th. The company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.56 by $0.03. The company had revenue of $388 million for the quarter, compared to analyst estimates of $384.58 million. During the same quarter last year, the business earned $0.47 EPS. The company’s revenue for the quarter was up 7.9% on a year-over-year basis. Equities research analysts expect that West Pharmaceutical Services Inc. will post $2.23 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Wednesday, August 3rd. Shareholders of record on Wednesday, July 20th were issued a dividend of $0.12 per share. The ex-dividend date was Monday, July 18th. This represents a $0.48 annualized dividend and a yield of 0.59%.

In other West Pharmaceutical Services news, Director Thomas W. Hofmann sold 2,466 shares of the stock in a transaction that occurred on Wednesday, May 25th. The stock was sold at an average price of $73.57, for a total transaction of $181,423.62. Following the transaction, the director now owns 34,506 shares in the company, valued at $2,538,606.42. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Daniel Malone sold 3,950 shares of the stock in a transaction that occurred on Thursday, June 2nd. The shares were sold at an average price of $74.95, for a total value of $296,052.50. Following the transaction, the vice president now owns 30,666 shares in the company, valued at approximately $2,298,416.70. The disclosure for this sale can be found here.

Other institutional investors recently made changes to their positions in the company. State of Wisconsin Investment Board increased its position in shares of West Pharmaceutical Services by 3.1% in the fourth quarter. State of Wisconsin Investment Board now owns 32,181 shares of the company’s stock valued at $1,938,000 after buying an additional 962 shares during the period. Principal Financial Group Inc. increased its position in shares of West Pharmaceutical Services by 2.8% in the fourth quarter. Principal Financial Group Inc. now owns 226,582 shares of the company’s stock valued at $13,645,000 after buying an additional 6,187 shares during the period. Advisors Asset Management Inc. boosted its stake in West Pharmaceutical Services by 6.1% in the fourth quarter. Advisors Asset Management Inc. now owns 31,111 shares of the company’s stock valued at $1,874,000 after buying an additional 1,789 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. boosted its stake in West Pharmaceutical Services by 6.7% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 302,423 shares of the company’s stock valued at $18,212,000 after buying an additional 19,121 shares in the last quarter.

West Pharmaceutical Services, Inc is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s products include stoppers and seals for vials, prefillable syringe components and systems, components for intravenous and blood collection systems, safety and administration systems, advanced injection systems, and contract design and manufacturing services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.